Just 800 of the 13,500 patients eligible to start receiving Wegovy, which can help obese people lose 15% of their body weight ...
One of the downsides of treatments such as Ozempic or Mounjaro is that even though patients wind up losing weight, they also tend to shed muscle mass. Losing too much muscle mass can be a health risk ...
PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...
A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's ...
2d
GlobalData on MSNObesity trial surge puts the focus back on decentralisationAs obesity clinical trials evolve, there is a growing emphasis on how decentralisation and new technologies can play a role.
Zealand Pharma CEO Adam Steensberg said Friday that the company is working on a next-generation weight loss drug that’s ...
Popular weight loss drugs are so pricey that many may shell out hundreds or even thousands of dollars on them. Some ...
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
Zealand Pharma's CEO Adam Steensberg weighs in on early-stage trials of its obesity drug contender and talks down takeover ...
Therapies that deliver hydrogen sulfide to cells could one day become the basis of new treatments for obesity and related ...
The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results